Determination That Alcohol and Dextrose Injection, 5 Milliliters/100 Milliliters, 5 Grams/100 Milliliters; and 10 Milliliters/100 Milliliters, 5 Grams/100 Milliliters, Were Withdrawn From Sale for Reasons of Safety or Effectiveness, 72606-72607 [2021-27696]
Download as PDF
<![CDATA[
72606
Federal Register / Vol. 86, No. 243 / Wednesday, December 22, 2021 / Notices
Dated: December 15, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021–27680 Filed 12–21–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–P–0375]
Determination That Alcohol and
Dextrose Injection, 5 Milliliters/100
Milliliters, 5 Grams/100 Milliliters; and
10 Milliliters/100 Milliliters, 5 Grams/
100 Milliliters, Were Withdrawn From
Sale for Reasons of Safety or
Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we)
has determined that Alcohol and
Dextrose Injection, 5 milliliters (mL)/
100 mL, 5 gram (g)/100 mL; and Alcohol
and Dextrose Injection, 10 mL/100 mL,
5 g/100 mL, were withdrawn from sale
for reasons of safety or effectiveness.
The Agency will not accept or approve
abbreviated new drug applications
(ANDAs) for Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL;
and 10 mL/100 mL, 5 g/100 mL.
FOR FURTHER INFORMATION CONTACT:
Kaetochi Okemgbo, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6272,
Silver Spring, MD 20993–0002, 240–
825–9944, Kaetochi.Okemgbo@
fda.hhs.gov.
SUMMARY:
Section
505(j) of the Federal Food, Drug, and
Cosmetic Act (FD&C Act) (21 U.S.C.
355(j)) allows the submission of an
ANDA to market a generic version of a
previously approved drug product. To
obtain approval, the ANDA applicant
must show, among other things, that the
generic drug product: (1) Has the same
active ingredient(s), dosage form, route
of administration, strength, conditions
of use, and, with certain exceptions,
labeling as the listed drug, which is a
version of the drug that was previously
approved; and (2) is bioequivalent to the
listed drug. ANDA applicants do not
have to repeat the extensive clinical
testing otherwise necessary to gain
approval of a new drug application
(NDA).
Section 505(j)(7) of the FD&C Act
requires FDA to publish a list of all
khammond on DSKJM1Z7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:55 Dec 21, 2021
Jkt 256001
approved drugs. FDA publishes this list
as part of the ‘‘Approved Drug Products
With Therapeutic Equivalence
Evaluations,’’ which is known generally
as the ‘‘Orange Book.’’ Under FDA
regulations, drugs are removed from the
list if the Agency withdraws or
suspends approval of the drug’s NDA or
ANDA for reasons of safety or
effectiveness or if FDA determines that
the listed drug was withdrawn from sale
for reasons of safety or effectiveness (21
CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (§ 314.161 (21 CFR 314.161)).
FDA may not approve an ANDA that
does not refer to a listed drug.
Between 1938 and 1968, FDA
evaluated NDAs solely on the basis of
safety information. In 1962, the
Kefauver-Harris Drug Amendments
(Pub. L. 87–781) amended the FD&C Act
to require that new drug products also
be shown to be effective in order to
obtain approval of an NDA. After the
enactment of the Kefauver-Harris Drug
Amendments, FDA initiated the Drug
Efficacy Study Implementation (DESI) to
evaluate the effectiveness of drug
products that had been approved
between 1938 and 1962 solely on the
basis of safety.
FDA introduced the concept of an
‘‘abbreviated new drug application’’ in
1968 as a vehicle for approval of certain
drugs affected by the DESI review.
When a drug product subject to the
DESI review was determined to be
effective for one or more indications,
FDA would issue a Federal Register
notice for that drug product describing
the DESI review findings and stating
whether abbreviated new drug
applications that met specified criteria
could be submitted to FDA (see
generally 35 FR 11273 (July 14, 1970);
35 FR 6574 (April 24, 1970)) for
products that had not been marketed
under an NDA. Such a finding allowed
manufacturers to submit an abbreviated
new drug application in lieu of an NDA.
For approval of these applications,
which were submitted before the Drug
Price Competition and Patent Term
Restoration Act of 1984 (Hatch-Waxman
Amendments) (Pub. L. 98–417) created
the current ANDA pathway, FDA relied
on the evidence of effectiveness that had
been provided, reviewed, and accepted
during the DESI process and evaluated
the safety of these drug products on the
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
basis of information included in NDAs
submitted prior to 1962, as well as the
subsequent marketing experience with
the drugs. These applications are
referred to as pre-Hatch-Waxman
abbreviated new drug applications or
‘‘PANDAs’’.1 PANDAs were submitted
under section 505(b) of the FD&C Act
and approved for safety and
effectiveness under section 505(c) of the
FD&C Act (see 86 FR 44731 at 44732
(August 13, 2021)).
As explained above, the current
ANDA pathway is described in section
505(j) of the FD&C Act. Because of
substantive differences in the
application approval pathway for
PANDAs, which were approved for
safety and effectiveness under section
505(c) of the FD&C Act, compared to
ANDAs approved under section 505(j)
of the FD&C Act, FDA has determined
that PANDA products can serve as
reference listed drugs for 505(j) ANDA
applicants seeking to make generic
versions of these products and that there
is a finding of safety and effectiveness
that may be relied upon for approval by
applicants of 505(b)(2) applications.
Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL; and 10 mL/100
mL, 5 g/100 mL, is the subject of NDA
004589, held by B. Braun Medical Inc.
The initial application, which included
Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL, was allowed to
take effect on February 21, 1942.
Alcohol and Dextrose Injection, 10 mL/
100 mL, 5 g/100 mL, was allowed to
take effect in a supplemental
application on January 17, 1946. On July
28, 1972, FDA published a Federal
Register notice regarding the DESI
review of NDA 004589 (see 37 FR
15184). Under the DESI review, FDA
concluded that there was substantial
evidence of efficacy for two
formulations of 5 percent Alcohol and 5
percent Dextrose for the indication ‘‘for
increasing caloric intake.’’ Based on the
Federal Register notice, FDA approved
Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL in three PANDAs:
ANDA 083263, held by Hospira, Inc.
and initially approved on February 26,
1974; ANDA 083483, held by Miles
Laboratories Inc. and originally
approved on November 22, 1974; and
1 See ‘‘Drug Products Approved in Abbreviated
New Drug Applications Before the Enactment of the
Hatch-Waxman Amendments; Establishment of a
Public Docket; Request for Comments,’’ 86 FR
44731 (August 13, 2021). Note that the scope of the
referenced notice is limited to drug products
approved in PANDAs under section 505 of the
FD&C Act prior to the Hatch-Waxman
Amendments; the notice does not cover
applications for antibiotic drug products that were
originally submitted under section 507 of the FD&C
Act (21 U.S.C. 357).
E:\FR\FM\22DEN1.SGM
22DEN1
Federal Register / Vol. 86, No. 243 / Wednesday, December 22, 2021 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
ANDA 083256, held by Baxter
Healthcare Corp. and initially approved
on March 12, 1976.2
All Alcohol and Dextrose Injection
products have been discontinued and
moved to the ‘‘Discontinued Product
List’’ section of the Orange Book. In a
letter dated June 23, 1999, Miles
Laboratories Inc. notified FDA that
Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL, the subject of
ANDA 083483, was being discontinued,
and FDA moved the drug product to the
‘‘Discontinued Drug Product List’’
section of the Orange Book. In the
Federal Register of September 22, 1999,
FDA announced it was withdrawing
approval of ANDA 083256, effective
September 22, 1999 (see 64 FR 51325).
Approval of ANDA 083256 was
withdrawn upon request of Baxter
Healthcare Corp. under § 314.150(c) (21
CFR 314.150(c)) because the product
was no longer being marketed. In the
Federal Register of June 19, 2014, FDA
announced it was withdrawing approval
of ANDA 083263, effective July 21, 2014
(see 79 FR 35170). Approval of ANDA
083263 was withdrawn upon request of
Hospira, Inc., under § 314.150(c)
because the product was no longer being
marketed. In the Federal Register of
October 13, 2015, FDA announced it
was withdrawing approval of NDA
004589, effective November 15, 2015
(see 80 FR 61426). Approval of NDA
004589 was withdrawn upon request of
B. Braun Medical Inc. under
§ 314.150(c) because the products were
no longer being marketed.
Celerity Pharmaceuticals, LLC
submitted a citizen petition dated April
12, 2021 (Docket No. FDA–2021–P–
0375), under 21 CFR 10.30, requesting
that the Agency determine whether B.
Braun Medical Inc.’s Alcohol and
Dextrose Injection, 10 mL/100 mL, 5 g/
100 mL, NDA 004589, was withdrawn
from sale for reasons of safety or
effectiveness. Although the citizen
petition did not address the 5 mL/100
mL, 5 g/100 mL strength or the
PANDAs, that strength and the PANDAs
have also been withdrawn from sale. On
our own initiative, we have also
2 The Orange Book refers to the Alcohol and
Dextrose Injection, 5 mL/100 mL, 5 g/100 mL
products in the three PANDAs (i.e., ANDA 083263,
ANDA 083483, and ANDA 083256) as Alcohol ‘‘in’’
Dextrose, but these products contain the same
concentrations of alcohol and dextrose as Alcohol
and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL,
approved under NDA 004589. Our findings are
limited to these products, which contain both
alcohol and dextrose, and we make no findings
about the safety or effectiveness of any product that
may contain only one of the active ingredients.
VerDate Sep<11>2014
17:55 Dec 21, 2021
Jkt 256001
determined whether the 5 mL/100 mL,
5 g/100 mL strength under NDA 004589
and the PANDAs were withdrawn from
sale for safety or effectiveness reasons.
The petitioner has identified no data
or other information suggesting that
Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL; or 10 mL/100 mL,
5 g/100 mL, were withdrawn for reasons
of safety or effectiveness. Specifically,
the petitioner states that the Alcohol
and Dextrose Injection, 10 mL/100 mL,
5 g/100 mL, was discontinued for
unknown reasons. The petitioner also
included a letter published on
November 15, 2005, in the American
Journal of Health-System Pharmacy,
which describes the use of Alcohol and
Dextrose Injection as a treatment for
ethylene glycol and methanol
poisonings.
We have carefully reviewed our files
for records concerning the withdrawal
of Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL; and 10 mL/100 mL,
5 g/100 mL, from sale. We have also
independently evaluated relevant
literature and data for possible
postmarketing adverse events. Based on
a thorough evaluation of the information
we have available to us and an
evaluation of the latest version of the
drug products’ approved labeling, we
have determined that the drug products
would not be considered safe and
effective if they were reintroduced to
the market today. Therefore, after
considering the citizen petition and
reviewing Agency records and based on
the information we have at this time,
FDA has determined under § 314.161
that Alcohol and Dextrose Injection,
5 mL/100 mL, 5 g/100 mL; and Alcohol
and Dextrose Injection, 10 mL/100 mL,
5 g/100 mL were withdrawn for reasons
of safety or effectiveness.
Alcohol and Dextrose Injection is
indicated to provide increased caloric
intake. The use of Alcohol and Dextrose
raises several safety concerns because
there are many risks associated with the
exposure to alcohol. Alcohol is
contraindicated for use in patients with
neurologic disorders, such as seizures,
who have current or past substance
abuse problems or who are pregnant. It
can cause intoxication, respiratory
depression, and disturbances in serum
glucose levels. FDA-approved
alternatives for intravenous calorie
supplementation that do not include
alcohol were approved after these
Alcohol and Dextrose products and are
available today.
In addition to the safety
considerations, we have concerns about
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
72607
the appropriateness of Alcohol and
Dextrose Injection to provide
intravenous nutrition. Alcohol and
Dextrose Injection was developed prior
to the advent of more physiologically
complete intravenous nutrition options.
Parenteral nutrition, delivered
intravenously, is used as a source of
nutrition when oral or enteral nutrition
cannot be administered. Parenteral
nutrition is an admixture of solutions
containing dextrose, amino acids,
electrolytes, vitamins, minerals, and
trace elements. Lipid emulsions are
infused separately or added to the
mixture, which allows for high energy
supply with iso-osmolar solutions.
Providing an adequate proportion of the
energy needs as lipids obviates the need
for high glucose infusion rates and,
therefore, can contribute to the
prevention of hepatic steatosis and
hyperglycemia. Lipid emulsions are also
necessary to supply essential fatty acids.
Today, there are several FDA-approved
parenteral products that are alternatives
to Alcohol and Dextrose for increasing
caloric intake and that also address
other nutritional needs.
Because new clinical studies would
first need to be conducted to address the
concerns described above, FDA has
determined that these Alcohol and
Dextrose products would not be
considered safe and effective if they
were reintroduced to the market.
Therefore, under § 314.161, FDA has
determined that Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL;
and 10 mL/100 mL, 5 g/100 mL were
withdrawn for safety and effectiveness
reasons. Accordingly, the Agency will
remove B. Braun Medical Inc.’s NDA
004589 for Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL;
and 10 mL/100 mL, 5 g/100 mL; Miles
Laboratory Inc.’s ANDA 083483 for
Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL; Baxter Healthcare
Corp’s ANDA 083256 for Alcohol and
Dextrose Injection, 5 mL/100 mL, 5 g/
100 mL; and Hospira, Inc.’s ANDA
083263 for Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL
from the list of drug products published
in the Orange Book. FDA will not accept
or approve ANDAs that refer to these
drug products.
Dated: December 15, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021–27696 Filed 12–21–21; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\22DEN1.SGM
22DEN1
]]>Agencies
[Federal Register Volume 86, Number 243 (Wednesday, December 22, 2021)]
[Notices]
[Pages 72606-72607]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27696]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-P-0375]
Determination That Alcohol and Dextrose Injection, 5 Milliliters/
100 Milliliters, 5 Grams/100 Milliliters; and 10 Milliliters/100
Milliliters, 5 Grams/100 Milliliters, Were Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has
determined that Alcohol and Dextrose Injection, 5 milliliters (mL)/100
mL, 5 gram (g)/100 mL; and Alcohol and Dextrose Injection, 10 mL/100
mL, 5 g/100 mL, were withdrawn from sale for reasons of safety or
effectiveness. The Agency will not accept or approve abbreviated new
drug applications (ANDAs) for Alcohol and Dextrose Injection, 5 mL/100
mL, 5 g/100 mL; and 10 mL/100 mL, 5 g/100 mL.
FOR FURTHER INFORMATION CONTACT: Kaetochi Okemgbo, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6272, Silver Spring, MD 20993-0002, 240-
825-9944, [email protected].
SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of
an ANDA to market a generic version of a previously approved drug
product. To obtain approval, the ANDA applicant must show, among other
things, that the generic drug product: (1) Has the same active
ingredient(s), dosage form, route of administration, strength,
conditions of use, and, with certain exceptions, labeling as the listed
drug, which is a version of the drug that was previously approved; and
(2) is bioequivalent to the listed drug. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
Section 505(j)(7) of the FD&C Act requires FDA to publish a list of
all approved drugs. FDA publishes this list as part of the ``Approved
Drug Products With Therapeutic Equivalence Evaluations,'' which is
known generally as the ``Orange Book.'' Under FDA regulations, drugs
are removed from the list if the Agency withdraws or suspends approval
of the drug's NDA or ANDA for reasons of safety or effectiveness or if
FDA determines that the listed drug was withdrawn from sale for reasons
of safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
Between 1938 and 1968, FDA evaluated NDAs solely on the basis of
safety information. In 1962, the Kefauver-Harris Drug Amendments (Pub.
L. 87-781) amended the FD&C Act to require that new drug products also
be shown to be effective in order to obtain approval of an NDA. After
the enactment of the Kefauver-Harris Drug Amendments, FDA initiated the
Drug Efficacy Study Implementation (DESI) to evaluate the effectiveness
of drug products that had been approved between 1938 and 1962 solely on
the basis of safety.
FDA introduced the concept of an ``abbreviated new drug
application'' in 1968 as a vehicle for approval of certain drugs
affected by the DESI review. When a drug product subject to the DESI
review was determined to be effective for one or more indications, FDA
would issue a Federal Register notice for that drug product describing
the DESI review findings and stating whether abbreviated new drug
applications that met specified criteria could be submitted to FDA (see
generally 35 FR 11273 (July 14, 1970); 35 FR 6574 (April 24, 1970)) for
products that had not been marketed under an NDA. Such a finding
allowed manufacturers to submit an abbreviated new drug application in
lieu of an NDA. For approval of these applications, which were
submitted before the Drug Price Competition and Patent Term Restoration
Act of 1984 (Hatch-Waxman Amendments) (Pub. L. 98-417) created the
current ANDA pathway, FDA relied on the evidence of effectiveness that
had been provided, reviewed, and accepted during the DESI process and
evaluated the safety of these drug products on the basis of information
included in NDAs submitted prior to 1962, as well as the subsequent
marketing experience with the drugs. These applications are referred to
as pre-Hatch-Waxman abbreviated new drug applications or ``PANDAs''.\1\
PANDAs were submitted under section 505(b) of the FD&C Act and approved
for safety and effectiveness under section 505(c) of the FD&C Act (see
86 FR 44731 at 44732 (August 13, 2021)).
---------------------------------------------------------------------------
\1\ See ``Drug Products Approved in Abbreviated New Drug
Applications Before the Enactment of the Hatch-Waxman Amendments;
Establishment of a Public Docket; Request for Comments,'' 86 FR
44731 (August 13, 2021). Note that the scope of the referenced
notice is limited to drug products approved in PANDAs under section
505 of the FD&C Act prior to the Hatch-Waxman Amendments; the notice
does not cover applications for antibiotic drug products that were
originally submitted under section 507 of the FD&C Act (21 U.S.C.
357).
---------------------------------------------------------------------------
As explained above, the current ANDA pathway is described in
section 505(j) of the FD&C Act. Because of substantive differences in
the application approval pathway for PANDAs, which were approved for
safety and effectiveness under section 505(c) of the FD&C Act, compared
to ANDAs approved under section 505(j) of the FD&C Act, FDA has
determined that PANDA products can serve as reference listed drugs for
505(j) ANDA applicants seeking to make generic versions of these
products and that there is a finding of safety and effectiveness that
may be relied upon for approval by applicants of 505(b)(2)
applications.
Alcohol and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL; and 10 mL/
100 mL, 5 g/100 mL, is the subject of NDA 004589, held by B. Braun
Medical Inc. The initial application, which included Alcohol and
Dextrose Injection, 5 mL/100 mL, 5 g/100 mL, was allowed to take effect
on February 21, 1942. Alcohol and Dextrose Injection, 10 mL/100 mL, 5
g/100 mL, was allowed to take effect in a supplemental application on
January 17, 1946. On July 28, 1972, FDA published a Federal Register
notice regarding the DESI review of NDA 004589 (see 37 FR 15184). Under
the DESI review, FDA concluded that there was substantial evidence of
efficacy for two formulations of 5 percent Alcohol and 5 percent
Dextrose for the indication ``for increasing caloric intake.'' Based on
the Federal Register notice, FDA approved Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL in three PANDAs: ANDA 083263, held
by Hospira, Inc. and initially approved on February 26, 1974; ANDA
083483, held by Miles Laboratories Inc. and originally approved on
November 22, 1974; and
[[Page 72607]]
ANDA 083256, held by Baxter Healthcare Corp. and initially approved on
March 12, 1976.\2\
---------------------------------------------------------------------------
\2\ The Orange Book refers to the Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL products in the three PANDAs
(i.e., ANDA 083263, ANDA 083483, and ANDA 083256) as Alcohol ``in''
Dextrose, but these products contain the same concentrations of
alcohol and dextrose as Alcohol and Dextrose Injection, 5 mL/100 mL,
5 g/100 mL, approved under NDA 004589. Our findings are limited to
these products, which contain both alcohol and dextrose, and we make
no findings about the safety or effectiveness of any product that
may contain only one of the active ingredients.
---------------------------------------------------------------------------
All Alcohol and Dextrose Injection products have been discontinued
and moved to the ``Discontinued Product List'' section of the Orange
Book. In a letter dated June 23, 1999, Miles Laboratories Inc. notified
FDA that Alcohol and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL, the
subject of ANDA 083483, was being discontinued, and FDA moved the drug
product to the ``Discontinued Drug Product List'' section of the Orange
Book. In the Federal Register of September 22, 1999, FDA announced it
was withdrawing approval of ANDA 083256, effective September 22, 1999
(see 64 FR 51325). Approval of ANDA 083256 was withdrawn upon request
of Baxter Healthcare Corp. under Sec. 314.150(c) (21 CFR 314.150(c))
because the product was no longer being marketed. In the Federal
Register of June 19, 2014, FDA announced it was withdrawing approval of
ANDA 083263, effective July 21, 2014 (see 79 FR 35170). Approval of
ANDA 083263 was withdrawn upon request of Hospira, Inc., under Sec.
314.150(c) because the product was no longer being marketed. In the
Federal Register of October 13, 2015, FDA announced it was withdrawing
approval of NDA 004589, effective November 15, 2015 (see 80 FR 61426).
Approval of NDA 004589 was withdrawn upon request of B. Braun Medical
Inc. under Sec. 314.150(c) because the products were no longer being
marketed.
Celerity Pharmaceuticals, LLC submitted a citizen petition dated
April 12, 2021 (Docket No. FDA-2021-P-0375), under 21 CFR 10.30,
requesting that the Agency determine whether B. Braun Medical Inc.'s
Alcohol and Dextrose Injection, 10 mL/100 mL, 5 g/100 mL, NDA 004589,
was withdrawn from sale for reasons of safety or effectiveness.
Although the citizen petition did not address the 5 mL/100 mL, 5 g/100
mL strength or the PANDAs, that strength and the PANDAs have also been
withdrawn from sale. On our own initiative, we have also determined
whether the 5 mL/100 mL, 5 g/100 mL strength under NDA 004589 and the
PANDAs were withdrawn from sale for safety or effectiveness reasons.
The petitioner has identified no data or other information
suggesting that Alcohol and Dextrose Injection, 5 mL/100 mL, 5 g/100
mL; or 10 mL/100 mL, 5 g/100 mL, were withdrawn for reasons of safety
or effectiveness. Specifically, the petitioner states that the Alcohol
and Dextrose Injection, 10 mL/100 mL, 5 g/100 mL, was discontinued for
unknown reasons. The petitioner also included a letter published on
November 15, 2005, in the American Journal of Health-System Pharmacy,
which describes the use of Alcohol and Dextrose Injection as a
treatment for ethylene glycol and methanol poisonings.
We have carefully reviewed our files for records concerning the
withdrawal of Alcohol and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL;
and 10 mL/100 mL, 5 g/100 mL, from sale. We have also independently
evaluated relevant literature and data for possible postmarketing
adverse events. Based on a thorough evaluation of the information we
have available to us and an evaluation of the latest version of the
drug products' approved labeling, we have determined that the drug
products would not be considered safe and effective if they were
reintroduced to the market today. Therefore, after considering the
citizen petition and reviewing Agency records and based on the
information we have at this time, FDA has determined under Sec.
314.161 that Alcohol and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL;
and Alcohol and Dextrose Injection, 10 mL/100 mL, 5 g/100 mL were
withdrawn for reasons of safety or effectiveness.
Alcohol and Dextrose Injection is indicated to provide increased
caloric intake. The use of Alcohol and Dextrose raises several safety
concerns because there are many risks associated with the exposure to
alcohol. Alcohol is contraindicated for use in patients with neurologic
disorders, such as seizures, who have current or past substance abuse
problems or who are pregnant. It can cause intoxication, respiratory
depression, and disturbances in serum glucose levels. FDA-approved
alternatives for intravenous calorie supplementation that do not
include alcohol were approved after these Alcohol and Dextrose products
and are available today.
In addition to the safety considerations, we have concerns about
the appropriateness of Alcohol and Dextrose Injection to provide
intravenous nutrition. Alcohol and Dextrose Injection was developed
prior to the advent of more physiologically complete intravenous
nutrition options. Parenteral nutrition, delivered intravenously, is
used as a source of nutrition when oral or enteral nutrition cannot be
administered. Parenteral nutrition is an admixture of solutions
containing dextrose, amino acids, electrolytes, vitamins, minerals, and
trace elements. Lipid emulsions are infused separately or added to the
mixture, which allows for high energy supply with iso-osmolar
solutions. Providing an adequate proportion of the energy needs as
lipids obviates the need for high glucose infusion rates and,
therefore, can contribute to the prevention of hepatic steatosis and
hyperglycemia. Lipid emulsions are also necessary to supply essential
fatty acids. Today, there are several FDA-approved parenteral products
that are alternatives to Alcohol and Dextrose for increasing caloric
intake and that also address other nutritional needs.
Because new clinical studies would first need to be conducted to
address the concerns described above, FDA has determined that these
Alcohol and Dextrose products would not be considered safe and
effective if they were reintroduced to the market. Therefore, under
Sec. 314.161, FDA has determined that Alcohol and Dextrose Injection,
5 mL/100 mL, 5 g/100 mL; and 10 mL/100 mL, 5 g/100 mL were withdrawn
for safety and effectiveness reasons. Accordingly, the Agency will
remove B. Braun Medical Inc.'s NDA 004589 for Alcohol and Dextrose
Injection, 5 mL/100 mL, 5 g/100 mL; and 10 mL/100 mL, 5 g/100 mL; Miles
Laboratory Inc.'s ANDA 083483 for Alcohol and Dextrose Injection, 5 mL/
100 mL, 5 g/100 mL; Baxter Healthcare Corp's ANDA 083256 for Alcohol
and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL; and Hospira, Inc.'s
ANDA 083263 for Alcohol and Dextrose Injection, 5 mL/100 mL, 5 g/100 mL
from the list of drug products published in the Orange Book. FDA will
not accept or approve ANDAs that refer to these drug products.
Dated: December 15, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-27696 Filed 12-21-21; 8:45 am]
BILLING CODE 4164-01-P
